Clinical Trial Detail

NCT ID NCT03769467
Title Tabelecleucel in Combination With Pembrolizumab in Subjects With EBV+ Nasopharyngeal Carcinoma (ATA129-NPC-202)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Atara Biotherapeutics
Indications

nasopharynx carcinoma

Therapies

Pembrolizumab + Tabelecleucel

Age Groups: child adult senior

No variant requirements are available.